DiBenedetti D, Kosa K, Waters HC, Oberdhan D. Understanding patients' experiences with borderline personality disorder: qualitative interviews. Neuropsychiatr Dis Treat. 2023 Oct 9;19:2115-25. doi: 10.2147/NDT.S423882
Alatalo A, de Sousa Maciel I, Kucharikova N, Chew S, van Kamp I, Foraster M, Julvez J, Kanninen KM. The interaction between circulating cell-free mitochondrial DNA and inflammatory cytokines in predicting human mental health issue risk in adolescents: an explorative study. Biomedicines. 2023 Mar 7;11(3):818. doi: 10.3390/biomedicines11030818
Carton-Garcia F, Saande CJ, Meraviglia-Crivelli D, Aldabe R, Pastor F. Oligonucleotide-based therapies for renal diseases. Biomedicines. 2021 Mar 16;9(3):303. doi: 10.3390/biomedicines9030303
Imagawa H, Nagar SP, Montgomery W, Nakamura T, Sato M, Davis KL. Treatment patterns, health care resource utilization, and costs in Japanese adults with attention-deficit hyperactivity disorder treated with atomoxetine. Neuropsychiatr Dis Treat. 2018 Feb 22;14:611-21. doi: 10.2147/NDT.S150261
Novick D, Montgomery W, Aguado J, Peng XM, Haro JM. Impact of anxiety symptoms on outcomes of depression: an observational study in Asian patients. Neuropsychiatr Dis Treat. 2016 Apr 11;12:795-800. doi: 10.2147/NDT.S90134
Quinlan SC, Hawes JCL, Mines D, Ahmed S, Lanes S, Mehta V, Holick CN, Santanello N, Mast TC. Performance of an administrative claims algorithm to estimate the incidence of pure red cell aplasia in chronic hepatitis C patients. Epidemiology reports. 2015;3(1). doi: 10.7243/2054-9911-3-1
Coles T, Coon C, DeMuro C, McLeod LD, Gnanasakthy A. Psychometric evaluation of the Sheehan Disability Scale in adult patients with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat. 2014 May 19;10:887-95. doi: 10.2147/NDT.S55220. eCollection 2014